Research

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients


Reference:

Yee, C. S., Farewell, V. T., Isenberg, D. A., Griffiths, B., Teh, L. S., Bruce, I. N., Ahmad, Y., Rahman, A., Prabu, A., Akil, M., McHugh, N. J., Edwards, C., D'Cruz, D., Khamashta, M. A. and Gordon, C., 2011. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology, 50 (5), pp. 982-988.

Related documents:

This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below. (Contact Author)

Official URL:

http://dx.doi.org/10.1093/rheumatology/keq376

Abstract

Methods. Data from two multi-centre studies were used in the analysis: in a cross-sectional and a longitudinal fashion. At every assessment, data were collected on SLEDAI-2000 and treatment. The cross-sectional analysis with receiver operating characteristic (ROC) curves was used to examine the appropriate SLEDAI-2000 score to define active disease and increase in therapy was the reference standard. In the longitudinal analysis, sensitivity to change of SLEDAI-2000 was assessed with multinomial logistic regression. ROC curves analysis was used to examine possible cut-points in score changes associated with change in therapy, and mean changes were estimated. Results. In the cross-sectional analysis, the most appropriate cut-off scores for active disease were 3 or 4. In the longitudinal analysis, the best model for predicting treatment increase was with the change in SLEDAI-2000 score and the score from the previous visit as continuous variables. The use of cut-points was less predictive of treatment change than the use of continuous score. The mean difference in the change in SLEDAI-2000 scores, adjusted for prior score, between patients with treatment increase and those without was 2.64 (95% CI 2.16, 3.14). Conclusions. An appropriate SLEDAI-2000 score to define active disease is 3 or 4. SLEDAI-2000 index is sensitive to change. The use of SLEDAI-2000 as a continuous outcome is recommended for comparative purposes.

Details

Item Type Articles
CreatorsYee, C. S., Farewell, V. T., Isenberg, D. A., Griffiths, B., Teh, L. S., Bruce, I. N., Ahmad, Y., Rahman, A., Prabu, A., Akil, M., McHugh, N. J., Edwards, C., D'Cruz, D., Khamashta, M. A. and Gordon, C.
DOI10.1093/rheumatology/keq376
DepartmentsFaculty of Science > Pharmacy & Pharmacology
Faculty of Humanities & Social Sciences > Health
RefereedYes
StatusPublished
ID Code25410

Export

Actions (login required)

View Item